The value of serum HE4 and ESM-1 levels in the evaluation patients with lung cancer receiving chemoradiotherapy

Background: to analyze the value of serum human epididymis protein 4 (he4) and endothelial cell specific molecule-1 (esm-1) in the evaluation of chemoradiotherapy in patients with lung cancer (lc). materials and methods: the patients were treated with chemoradiotherapy alone combined with bevacizumab targeted drug therapy. 45 healthy subjects were selected as the control group. according to different clinical effects, it is divided into progression (pd), stability (sd), partial remission (pr) and complete remission (cr). among them, pr group + cr group + sd group is regarded as the effective group, and pd group is regarded as the ineffective group, cr + pr = disease effective rate (rr), sd + pr + cr = disease control rate (dcr). results: compared with the control group, serum he4 and esm-1 in the study group was decreased (p < 0.05). compared with before treatment, the levels of serum he4 and esm-1 in cr, pr and sd groups decreased (p < 0.05), and these in cr group were decreased than those in pr group (p < 0.05), the levels of serum he4 and esm-1 in pr group were decreased than those in sd group (p < 0.05). the best cutoff points of serum he4 and esm-1 levels for the diagnosis of therapeutic effect of lc were 69.88 ng/ml and 27.58ng/ml respectively. conclusion: the levels of serum he4 and esm-1 have obvious diagnostic value for the effect of chemoradiotherapy and targeted drugs in patients with lc, and they play critical role in the evaluation of the effect of drugs in patients with lc.